Drug Transporter (DT) Information

General Information of DT
DT ID DTD0133
Gene Name SLC1A5
Protein Name Alanine/serine/cysteine/threonine transporter 2
Gene ID
6510
UniProt ID
Q15758
TCDB ID
2.A.23.3.3
3D Structure

Modelled DT Structure

Method: loop building

Template PDB: 6GCT_A

Identity: 100%

Minimized Score: -1199.518 kcal/mol

Detail: Structure Info

Synonyms AAAT; ASCT2; ATB(0); ATBO; Baboon M7 virus receptor; M7V1; M7VS1; Neutral amino acid transporter B(0); R16; RD114/simian type D retrovirus receptor; RDR; RDRC; SLC1A5; Sodium-dependent neutral amino acid transporter type 2; Solute carrier family 1 member 5
DT Family Dicarboxylate/Amino Acid:Cation (Na(+) Or H(+)) Symporter (DAACS) Family ;
Tissue Specificity Placenta, lung, skeletal muscle, kidney,pancreas, and intestine.
Function This sodium-dependent amino acids transporter that has a broad substrate specificity, with a preference for zwitterionic amino acids. It accepts as substrates all neutral amino acids, including glutamine, asparagine, and branched-chain and aromatic amino acids, and excludes methylated, anionic, and cationic amino acids. Through binding of the fusogenic protein syncytin-1/ERVW-1 may mediate trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development.
Disease(s) Dietary shortage [ICD-11: 5B7Z]
Nutritional deficiency [ICD-11: 5B7Z]
Herpes simplex virus infection [ICD-11: 1F00]
Shingles [ICD-11: 1.00E+91]
Endogenous Substrate(s) Thyroid hormones; Thyroid hormone derivatives
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(α) Mutation-induced Structural Variation
Mutation-induced Structural Variation (MSV)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

(γ) Outward/inward-facing Conformation
Outward/inward-facing Conformation (OIC)

(δ) Xenobiotics-regulated Structural Variability
Xenobiotics-regulated Structural Variability (XSV)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            7 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Acyclovir
 Approved Drug Info Shingles 1.00E+91 [1]
Ganciclovir
 Approved Drug Info Cytomegalovirus infections 1D82 [1]
Glycine
 Approved Drug Info Dietary shortage 5B7Z [2]
L-carnitine
 Approved Drug Info Nutritional deficiency 5B7Z [3]
L-glutamine
 Approved Drug Info Short bowel syndrome KB89.1 [4]
Valacyclovir
 Approved Drug Info Shingles 1.00E+91 [5]
Valganciclovir
 Approved Drug Info Cytomegalovirus infections 1D82 [6]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
D-serine
 Phase 4 Drug Info Serine deficiency disorder 5C50.6 [7]
Nitric oxide
 Phase 2/3 Drug Info Platelet dysfunction 3B62 [8]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
L-threonine
 Preclinical Drug Info Ulcerative colitis DD71 [7]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Glycine Approved Drug Info HRPE cells-ASCT2 Km = 320 microM [2]

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
D-serine Phase 4 Drug Info Oocytes-ASCT2 Km = 167 microM [7]
References
1 Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64.
2 Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). Am J Physiol Gastrointest Liver Physiol. 2007 Nov;293(5):G1046-53.
3 A polarized localization of amino acid/carnitine transporter B(0,+) (ATB(0,+)) in the blood-brain barrier. Biochem Biophys Res Commun. 2008 Nov 14;376(2):267-70.
4 High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5.
5 Transport of amino acid-based prodrugs by the Na+- and Cl(-) -coupled amino acid transporter ATB0,+ and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther. 2004 Mar;308(3):1138-47.
6 Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). Pharm Res. 2004 Jul;21(7):1303-10.
7 D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
8 Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.